ProPhase Labs Q2 2024 GAAP EPS $(0.33) Misses $(0.12) Estimate, Sales $2.474M Miss $11.175M Estimate
Portfolio Pulse from Benzinga Newsdesk
ProPhase Labs (NASDAQ:PRPH) reported Q2 2024 GAAP EPS of $(0.33), missing the $(0.12) estimate by 175%. Sales were $2.474M, missing the $11.175M estimate by 77.86%. This represents a significant decline from the same period last year.
August 14, 2024 | 12:08 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
ProPhase Labs reported Q2 2024 GAAP EPS of $(0.33), missing the $(0.12) estimate by 175%. Sales were $2.474M, missing the $11.175M estimate by 77.86%. This represents a significant decline from the same period last year.
The significant miss on both EPS and sales estimates, along with the drastic year-over-year declines, is likely to negatively impact investor sentiment and the stock price in the short term.
CONFIDENCE 100
IMPORTANCE 100
RELEVANCE 100